NCCN Lists Ropeginterferon Alfa-2B as Preferred First-Line Cytoreductive Therapy for Polycythemia Vera
The National Comprehensive Cancer Network (NCCN) recommends ropeginterferon alfa-2b as first-line cytoreductive therapy for polycythemia vera.
Read More